Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) traded down 8.1% on Tuesday after Morgan Stanley lowered their price target on the stock from $57.00 to $53.00. Morgan Stanley currently has an overweight rating on the stock. Avalyn Pharma traded as low as $27.04 and last traded at $27.36. 28,822 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 340,475 shares. The stock had previously closed at $29.76.
A number of other brokerages also recently issued reports on AVLN. Raymond James Financial began coverage on Avalyn Pharma in a research report on Friday, October 2nd. They set an "outperform" rating and a $60.00 price target on the stock. Wall Street Zen upgraded Avalyn Pharma from a "sell" rating to a "hold" rating in a research report on Saturday. Finally, Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Avalyn Pharma in a research note on Wednesday, November 11th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $59.20.
View Our Latest Analysis on Avalyn Pharma
Insider Activity at Avalyn Pharma
In other news, insider Fmr Llc sold 175,000 shares of the firm's stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $29.07, for a total value of $5,087,250.00. Following the transaction, the insider owned 2,109,535 shares in the company, valued at $61,324,182.45. This trade represents a 7.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the company. Soleus Capital Management L.P. grew its holdings in shares of Avalyn Pharma by 143.2% during the third quarter. Soleus Capital Management L.P. now owns 1,019,000 shares of the company's stock worth $29,031,000 after buying an additional 600,000 shares in the last quarter. State Street Corp boosted its position in Avalyn Pharma by 73.7% during the third quarter. State Street Corp now owns 554,004 shares of the company's stock worth $15,784,000 after acquiring an additional 235,009 shares during the last quarter. Profund Advisors LLC purchased a new stake in Avalyn Pharma during the 3rd quarter valued at about $668,000. China Universal Asset Management Co. Ltd. acquired a new stake in Avalyn Pharma in the 3rd quarter valued at about $29,000. Finally, Manchester Capital Management LLC acquired a new stake in Avalyn Pharma in the 3rd quarter valued at about $36,000.
Avalyn Pharma Stock Performance
The company has a quick ratio of 33.12, a current ratio of 33.12 and a debt-to-equity ratio of 0.04. The stock has a 50 day moving average of $28.51. The firm has a market capitalization of $1.22 billion and a price-to-earnings ratio of -1.21.
Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.03). Equities research analysts expect that Avalyn Pharma Inc. will post -3.83 earnings per share for the current fiscal year.
Avalyn Pharma Company Profile
(
Get Free Report)
Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company's pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn's inhaled candidates are being studied as potential alternatives to oral treatment.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Avalyn Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalyn Pharma wasn't on the list.
While Avalyn Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.